Synlogic announces decision to discontinue Synpheny-3 study of labafenogene marselecobac and provides corporate update.
Synlogic, Inc , a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB 1934) as a potential treatment for phenylketonuria (PKU)
As a result, Synlogic’s management and its Board of Directors have made the decision to evaluate strategic options for the Company. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee (DMC) assessment, which indicated the trial was unlikely to meet its primary endpoint. The decision was not based on concerns regarding safety or tolerability. Synlogic will now work with the Synpheny-3 clinical trial sites involved to implement the discontinuation.
Synlogic’s Board of Directors plans to conduct an assessment of strategic options to enhance shareholder value, which will include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, dissolution or other strategic transactions. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements will be reached, or transactions will be successfully consummated or on attractive terms.
As a result of this process, Synlogic will cease operations, and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review and assist in the discontinuation of the study.
Related news and insights
The FDA has granted regular approval to tepotinib (Tepmetko) for the treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations